Source: ERS webinar 2021: Understanding new vaccines for SARS-CoV-2 and their regulation
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Simonds (London, United Kingdom), T. Welte (Hannover, Germany), M. Cavaleri (Amsterdam, Netherlands), R. Boyton (London, United Kingdom). Understanding new vaccines for SARS-CoV-2 and their regulation. ERS webinar 2021: Understanding new vaccines for SARS-CoV-2 and their regulation

Member's Comments

Bipen Patel - 05.02.2021 16:40
Excellent, but almost too much information to assimilate in the time allowed.

Related content which might interest you: COVID-19 vaccination and more Source: ERS webinar 2021: COVID-19 vaccination and more Year: 2021 Medical staff attitude to vaccination against an influenza virus Source: Annual Congress 2013 –Epidemiology of respiratory disease Year: 2013 Seasonal influenza vaccine effectiveness in people with asthma: A systematic review Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Development of RSV vaccines: where are we? Source: International Congress 2019 – Respiratory syncytial virus infections throughout life Year: 2019 New Influenza vaccines Source: Virtual Congress 2021 – Vaccination and infections Year: 2021 New treatments for RSV and other viruses, including update on vaccines Source: ERS Courses: Paediatric respiratory infections Year: 2019 Age and impact of vaccine on seasonal H1N1p severe infection Source: International Congress 2016 – Viral infections in different respiratory conditions: from the bedside to the lab Year: 2016 Rapid spread of the novel respiratory syncytial virus A ON1 genotype, during the epidemic seasons 2011-2013 Source: International Congress 2014 – Virus-triggered lower respiratory disease in children Year: 2014 The first H7N9 influenza case of Shanghai in 2014: Reemerged virus with different origin of PB2 gene Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014 SARS-CoV-2 (COVID-19): Research response Source: Webinar 2020: SARS-CoV-2 (COVID-19): research response Year: 2020 State of the art in vaccine development against TB Source: Eur Respir Mon 2012; 58: 59-71 Year: 2012 ERS/ATS joint webinar: Rehabilitation after COVID 19 disease Source: ERS webinar 2020: ERS/ATS joint webinar: Rehabilitation after COVID 19 disease Year: 2020 ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Programme Source: ERS webinar 2020: ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Programme Year: 2020 ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Assessment Source: ERS webinar 2020: ERS/ATS joint webinar on rehabilitation after COVID 19 disease: Q&A on Assessment Year: 2020 Influenza: vaccination and treatment Source: Eur Respir J 2001; 17: 1282-1293 Year: 2001 Antibody epitope and mimotope prediction of the viroporins M2 of the Influenza A virus, E of the Human SARS coronavirus and SH of the Respiratory Syncytial virus. Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 Pneumococcal vaccine: when, what, how and to whom Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination? Year: 2014 Interview on Coronavirus COVID-19 management experience in China Source: Webinar 2020: Interview on Coronavirus COVID-19 management experience in China Year: 2020 Clinical and epidemiological features in H1N1 and H3N2 influenza A virus Source: International Congress 2015 – Viral infections: basic research and clinical perspective Year: 2015 Ebola: progress with vaccines Source: International Congress 2015 – Pandemics and emerging infections Year: 2015